(no title) Improving the treatment of Neglected Tropical Diseases The latest Oxfendazole Development Group Announces Enrollment of First Patient in Phase 2 Trial of Oxfendazole for Trichuris trichiura Infection Trichuris Trichiura infection classified as a neglected tropical disease by the WHO and CDC is caused by a parasitic whipworm and affects 800 million people worldwide Blue Bell PA October 2024 The Oxfendazole Development Group a notforprofit organization developing the widely used veterinary deworming treatment oxfendazole for public health use today announced the enrollment of the first patient in a Phase 2 clinical trial evaluating the safety and efficacy of this investigational medicine in people infected with the parasitic whipworm Trichuris trichiura. It is estimated that 800 million people worldwide have trichuriasis the infection caused by Trichuris trichiura. 1 This assessorblind randomized study has a planned enrollment of 249 participants and will compare the efficacy and safety of a single oral dose of either 400 mg or 800 mg of oxfendazole to the current standard of care a single oral 400 mg dose of albendazole. The trial will be conducted in the Amazonian region of Peru where there is a high prevalence of T.